for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AzurRx BioPharma Inc

AZRX.OQ

Latest Trade

0.82USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.40

 - 

2.28

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Azurrx Biopharma - CEO Issued Letter To Shareholders

April 21 (Reuters) - AzurRx BioPharma Inc <AZRX.O>::AZURRX BIOPHARMA - JAMES SAPIRSTEIN, PRESIDENT AND CEO ISSUED LETTER TO SHAREHOLDERS.AZURRX BIOPHARMA - DESPITE COVID-19, CURRENTLY ANTICIPATE ONLY MINOR DELAYS IN INITIATING & COMPLETING PHASE 2 OPTION 2 MONOTHERAPY CLINICAL TRIAL.AZURRX BIOPHARMA - BARRING ANY SIGNIFICANT CORONAVIRUS DEVELOPMENTS, SHOULD BE ABLE TO INITIATE OPTION 2 TRIAL BY END OF Q2 2020, EXPECT TOP LINE DATA IN Q1 2021.AZURRX BIOPHARMA - ANTICIPATE COMPLETION OF COMBINATION TRIAL BY END OF 2020 AND TOP LINE DATA IN Q1 2021.AZURRX BIOPHARMA - SUPPLY CHAIN REMAINS INTACT AND, AS OF TODAY, HAS NOT BEEN IMPACTED BY COVID-19.AZURRX BIOPHARMA - IN Q1 2020, RECEIVED $1.77 MILLION IN NON-DILUTIVE FUNDING FROM FRENCH RESEARCH AND DEVELOPMENT TAX CREDIT FOR 2017, 2018, ANTICIPATE RECEIVING 2019 CIR TOWARDS END OF YEAR.AZURRX BIOPHARMA - IN APRIL 2020, RECEIVED CARES ACT PAYCHECK PROTECTION PROGRAM LOAN OF ABOUT $180,000, WILL BE USED TO PAY EMPLOYEES, OTHER ELIGIBLE EXPENSES.AZURRX BIOPHARMA - PLAN TO SPEND 2020, EARLY 2021 FOCUSING ON NECESSARY CMC & REGULATORY OBJECTIVES NEEDED TO FULLY DEVELOP MS1819 FOR PHASE 3, COMMERCIALIZATION.

Azurrx Biopharma Inc Files Prospectus Relates To Offer, Sale Of Up To 11.6 Million Shares Of Common Stock By Certain Of Shareholders

Feb 7 (Reuters) - AzurRx BioPharma Inc <AZRX.O>::AZURRX BIOPHARMA INC FILES PROSPECTUS RELATES TO OFFER, SALE OF UP TO 11.6 MILLION SHARES OF COMMON STOCK BY CERTAIN OF SHAREHOLDERS - SEC FILING.

AzurRx Biopharma Announces Appointment Of Daniel Schneiderman As CFO

Jan 3 (Reuters) - AzurRx BioPharma Inc <AZRX.O>::AZURRX BIOPHARMA ANNOUNCES APPOINTMENT OF DANIEL SCHNEIDERMAN AS CHIEF FINANCIAL OFFICER.AZURRX BIOPHARMA - DANIEL SCHNEIDERMAN MOST RECENTLY SERVED AS CHIEF FINANCIAL OFFICER FOR BIOPHYTIS, SA.AZURRX BIOPHARMA - DANIEL SCHNEIDERMAN HAS BEEN APPOINTED TO SERVE AS CO'S CFO EFFECTIVE JAN 2, 2020.

Azurrx Biopharma Announces Equity Purchase Agreement For Up To $15 Mln With Lincoln Park Capital Fund

Nov 14 (Reuters) - AzurRx BioPharma Inc <AZRX.O>::AZURRX BIOPHARMA, INC. ANNOUNCES EQUITY PURCHASE AGREEMENT FOR UP TO $15 MILLION WITH LINCOLN PARK CAPITAL FUND, LLC.AZURRX BIOPHARMA - HAS ENTERED INTO A $15 MILLION COMMON STOCK PURCHASE AND REGISTRATION RIGHTS AGREEMENT WITH LINCOLN PARK CAPITAL FUND, LLC.AZURRX BIOPHARMA - LINCOLN PARK HAS AGREED NOT TO CAUSE OR ENGAGE IN ANY DIRECT OR INDIRECT SHORT SELLING OR HEDGING OF COMPANY'S COMMON STOCK.AZURRX BIOPHARMA - UNDER PURCHASE AGREEMENT, AZURRX WILL HAVE RIGHT TO SELL UP TO $15 MILLION OF ITS STOCK TO LINCOLN PARK OVER A 30-MONTH PERIOD.

Azurrx Biopharma Announces Positive Cff Dsmb Review Of Final Phase 2 Option Trial Data

Oct 17 (Reuters) - AzurRx BioPharma Inc <AZRX.O>::AZURRX BIOPHARMA ANNOUNCES POSITIVE CFF DSMB REVIEW OF FINAL PHASE 2 OPTION TRIAL DATA.AZURRX BIOPHARMA INC - NO SAFETY CONCERNS CITED FOR MS1819-SD.AZURRX BIOPHARMA - POSITIVE REVIEW SUPPORTS PLAN TO PROCEED TO HIGHER 4-GRAM DOSE OF MS1819-SD IN NEXT PHASE 2 TRIAL.AZURRX BIOPHARMA - LOOK FORWARD TO INITIATING NEXT PHASE 2 STUDY OF MS1819-SD AT HIGHER DOSE IN EARLY 2020.AZURRX BIOPHARMA - SAFETY PROFILE OF MS1819 AT 2-GRAM DOSE IN BOTH PHASE 2 STUDIES FOR CYSTIC FIBROSIS REPORTED NO SERIOUS ADVERSE EVENTS.

AzurRx Biopharma Announces Appointment Of James Sapirstein As Chief Executive Officer

Oct 10 (Reuters) - AzurRx BioPharma Inc <AZRX.O>::AZURRX BIOPHARMA ANNOUNCES APPOINTMENT OF JAMES SAPIRSTEIN AS CHIEF EXECUTIVE OFFICER.AZURRX BIOPHARMA INC - RESIGNATION OF THIJS SPOOR.AZURRX BIOPHARMA INC - SAPIRSTEIN RECENTLY SERVED AS CHIEF EXECUTIVE OFFICER AND BOARD MEMBER FOR CONTRAVIR PHARMACEUTICALS.

AzurRx Biopharma Announces Positive Results From Phase 2 Trial With MS1819 In Cystic Fibrosis Patients

Sept 25 (Reuters) - AzurRx BioPharma Inc <AZRX.O>::AZURRX BIOPHARMA ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH MS1819 IN CYSTIC FIBROSIS PATIENTS.AZURRX BIOPHARMA - POSITIVE SAFETY RESULTS FROM PHASE II OPTION CLINICAL TRIAL OF MS1819 FOR TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY IN CF.AZURRX BIOPHARMA - CO IS PLANNING TO MEET WITH FDA BEFORE YEAR-END TO DISCUSS PHASE IIB/III TRIAL DESIGN.

AzurRx BioPharma Says On Track To Announce Final Data Analysis Of Option Study In September 2019

Aug 13 (Reuters) - AzurRx BioPharma Inc <AZRX.O>::AZURRX BIOPHARMA REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.AZURRX BIOPHARMA INC - REMAIN ON TRACK TO ANNOUNCE FINAL DATA ANALYSIS OF OPTION STUDY IN SEPTEMBER 2019.

Azurrx Biopharma Announces Proposed Public Offering Of Common Stock

July 17 (Reuters) - AzurRx BioPharma Inc <AZRX.O>::AZURRX BIOPHARMA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.AZURRX BIOPHARMA - TO USE NET PROCEEDS FOR RESEARCH AND DEVELOPMENT EXPENSES ASSOCIATED WITH AZURRX'S CONTINUING CLINICAL DEVELOPMENT AND TESTING OF MS1819-SD.AZURRX BIOPHARMA INC - NET PROCEEDS FROM OFFERING PRIMARILY FOR ADVANCING ITS PRECLINICAL PROGRAMS FOR AZX1103.

AzurRx BioPharma Announces Initiation Of Phase 2 Clinical Study For Ms1819-Sd

July 8 (Reuters) - AzurRx BioPharma Inc <AZRX.O>::AZURRX BIOPHARMA ANNOUNCES INITIATION OF PHASE 2 CLINICAL STUDY FOR MS1819-SD IN COMBINATION WITH STANDARD PERT FOR CYSTIC FIBROSIS PATIENTS WITH SEVERE EXOCRINE PANCREATIC INSUFFICIENCY.AZURRX BIOPHARMA INC - PRELIMINARY DATA EXPECTED IN EARLY 2020..AZURRX BIOPHARMA INC - PRELIMINARY DATA EXPECTED IN EARLY 2020..

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up